Innate Pharma (IPHA) Operating Expenses (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Operating Expenses data on file, last reported at -$73.3 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 4.26% year-over-year to -$73.3 million; the trailing twelve-month figure through Dec 2025 stood at -$225.9 million (up 6.82% YoY), and the FY2025 full-year result was $73.3 million, down 4.26% from the prior year.
• Operating Expenses for Q4 2025 stood at -$73.3 million, down from -$34.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $8.7 million in Q2 2021 and bottomed at -$83.0 million in Q4 2021.
• The 5-year median for Operating Expenses is -$42.9 million (2023), against an average of -$46.4 million.
• The widest annual swing landed in 2021, when Operating Expenses surged 117.27%; it then slumped 105659.03% in 2023.
• A 5-year view of Operating Expenses shows it stood at -$83.0 million in 2021, then surged by 99.91% to -$75599.3 in 2022, then plunged by 105659.03% to -$80.0 million in 2023, then increased by 4.18% to -$76.6 million in 2024, then grew by 4.26% to -$73.3 million in 2025.
• The last three Operating Expenses figures came in at -$73.3 million (Q4 2025), -$34.3 million (Q2 2025), and -$76.6 million (Q4 2024), per Business Quant data.

Peer Comparison